Back

Long-term clinical benefit of mavacamten for hypertrophic cardiomyopathy in a patient with RAF1-associated noonan syndrome

11 May 2026 (13:03 - 13:15)
Organised by: Logo
Congress Presentation Part of: Myosin inhibition in hypertrophic cardiomyopathy: beyond the classic left ventricular outflow tract story Clinical Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Mrs Hanna Maria Seghers

University Hospital Antwerp, Edegem (Belgium)

3 More presentations in this session

Presentation thumbnail
Mavacamten for symptomatic mid-ventricular obstruction in apical hypertrophic cardiomyopathy
Doctor H. Choi (Seoul, KR)
Slides Video
Presentation thumbnail
Mavacamten therapy in hypertrophic obstructive cardiomyopathy revealing severe aortic stenosis: a case highlighting diagnostic complexity
Mrs G. Dumitru Ionescu (Bucharest, RO)
Slides Video
Presentation thumbnail
Expanding the role of myosin inhibition: mavacamten in apical hypertrophic cardiomyopathy with mid-ventricular obstruction
Doctor J. Fernandes Pedro (Lisbon, PT)
Slides Video

Access the full session

Session thumbnail
Myosin inhibition in hypertrophic cardiomyopathy: beyond the classic left ventricular outflow tract story
Video

The Event

Event poster

Heart Failure 2026

11 May 2026 13:03 CET
You may be interested in
thumbnail
Congress Presentation
Therapeutic response to myosin inhibitor therapy in noonan syndrome-associated obstructive hypertrophic cardiomyopathy
thumbnail
Congress Session
Myosin inhibition in hypertrophic cardiomyopathy: beyond the classic left ventricular outflow tract story
thumbnail
Congress Presentation
Delayed presentation of a patient with noonan syndrome and multiple lentigines with an advanced cardiac phenotype

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources